ZYBERNO
Stock Report
Updated Sep 1, 2026

BETTERLIFE PHARMA INC. (BETRF)

Healthcare • OTC

$0.22

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
BETTERLIFE PHARMA INC. (BETRF) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):GOOD (0.59x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-115.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BETTERLIFE PHARMA INC. (BETRF) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.22
Market Cap:$21.42M

Valuation Multiples (2)

P/B Ratio:8.93x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$22.18M

Price Action & Momentum (1)

% of 52-Week High:46.8%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:17.6%
Fundamental Growth Rate (g):-20.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.04x
Quick Ratio:0.04x
Cash Ratio:0.01x

Leverage Analysis (3)

Debt To Equity Ttm:0.59x
Debt-to-Equity Ratio:0.59x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-20.12x
Times Interest Earned:-20.12

Capital Structure (4)

Working Capital:-3,647,014.89
Cash And Cash Equivalents:32,329.86
Long Term Debt:$615.02K
Net Debt:$760.01K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$4.87M

Bottom Line Performance (3)

-$6.51M
Income Before Tax:-$6.51M
Ebitda Ttm:-4,231,088.10

Operating Expenses (5)

Operating Expenses:4,315,639.51
R And D Expense:42,348.32
Sga Expense:392,683.19
Income Tax Expense:$0.00
Interest Expense:242,131.55

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.80M
Current Assets:$138.00K
Ppe Net:2,962.89
Goodwill:0.00
Intangible Assets:$5.88M

Liability Structure (4)

Total Liabilities:4,400,035.02
Current Liabilities:3,785,013.01
Long Term Debt:$615.02K
Short Term Debt:$177.32K

Equity & Capital (3)

Equity:$2.40M
Retained Earnings:-$26.24M
Common Stock:16,340,529.06

Working Capital Items (3)

Accounts Receivable:5,649.57
Inventory:0.00
Accounts Payable:906,525.41

Special Items (2)

Contract Liabilities:112,285.30
Stock Based Compensation:4,197.32
C. Cash Flow Analysis

Operating Activities (2)

-$3.54M$0.00

Investment Activities (1)

Investing Cash Flow:-$303.38K

Financing Activities (3)

Financing Cash Flow:$374.46K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:292,012.40
Long Term Debt Issuance:$3.25M
Long Term Debt Repayments:$11.34K
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.07

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.04

Book Value & Capital (2)

Book Value Per Share:$0.02
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:17.6%
Fundamental Growth Rate (g):-20.4%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BETRF
Company Name:BETTERLIFE PHARMA INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:Canada

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:99.54M
Shares Outstanding Basic:99.54M
Shares Outstanding Diluted:99.54M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:37:03 UTC
Data Timestamp:2026-08-21T20:57:25.099753
Scroll to Top